Global Platinum based Cancer Drug Market Research Report 2024 - Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2031
ReportID: 543956
|
Published Date: 2024/07/06
|
No. of Pages: 165
|
Categories: Life Sciences
|
Format : 
The global Platinum based Cancer Drug market was valued at 131.45 Million USD in 2020 and will grow with a CAGR of 3.71% from 2020 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, popular drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development.The classification of platinum based cancer drug includes cisplatin, oxaliplatin, carboplatin and other types. The proportion of oxaliplatin in 2017 is about 71%, and the proportion is in decreasing trend from 2013 to 2017. Asia-Pacific is the largest market, with a sales market share nearly 53% in 2017. Following Asia-Pacific, Europe is the second largest sales place with the sales market share of 17%.
By Market Verdors:
Sanofi
Hengrui Medicine
ASK Pharma
Yi Bai Pharmaceutical
Qilu Pharmaceutical
Teva
Pfizer
Dr Reddys Laboratories
Mylan
Sun Pharma
Novartis
Debiopharm
Accord Healthcare
SK Chemicals
By Types:
Cisplatin
Oxaliplatin
Carboplatin
By Applications:
Colorectal Cancer
Ovarian Cancer
Lung Cancer
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, popular drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development.The classification of platinum based cancer drug includes cisplatin, oxaliplatin, carboplatin and other types. The proportion of oxaliplatin in 2017 is about 71%, and the proportion is in decreasing trend from 2013 to 2017. Asia-Pacific is the largest market, with a sales market share nearly 53% in 2017. Following Asia-Pacific, Europe is the second largest sales place with the sales market share of 17%.
By Market Verdors:
Sanofi
Hengrui Medicine
ASK Pharma
Yi Bai Pharmaceutical
Qilu Pharmaceutical
Teva
Pfizer
Dr Reddys Laboratories
Mylan
Sun Pharma
Novartis
Debiopharm
Accord Healthcare
SK Chemicals
By Types:
Cisplatin
Oxaliplatin
Carboplatin
By Applications:
Colorectal Cancer
Ovarian Cancer
Lung Cancer
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Platinum based Cancer Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Platinum based Cancer Drug Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Cisplatin
1.4.3 Oxaliplatin
1.4.4 Carboplatin
1.5 Market by Application
1.5.1 Global Platinum based Cancer Drug Market Share by Application: 2022-2027
1.5.2 Colorectal Cancer
1.5.3 Ovarian Cancer
1.5.4 Lung Cancer
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Platinum based Cancer Drug Market
1.8.1 Global Platinum based Cancer Drug Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Platinum based Cancer Drug Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Platinum based Cancer Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Platinum based Cancer Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Platinum based Cancer Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Platinum based Cancer Drug Sales Volume Market Share by Region (2016-2021)
3.2 Global Platinum based Cancer Drug Sales Revenue Market Share by Region (2016-2021)
3.3 North America Platinum based Cancer Drug Sales Volume
3.3.1 North America Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.3.2 North America Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Platinum based Cancer Drug Sales Volume
3.4.1 East Asia Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Platinum based Cancer Drug Sales Volume (2016-2021)
3.5.1 Europe Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Platinum based Cancer Drug Sales Volume (2016-2021)
3.6.1 South Asia Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Platinum based Cancer Drug Sales Volume (2016-2021)
3.7.1 Southeast Asia Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Platinum based Cancer Drug Sales Volume (2016-2021)
3.8.1 Middle East Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Platinum based Cancer Drug Sales Volume (2016-2021)
3.9.1 Africa Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Platinum based Cancer Drug Sales Volume (2016-2021)
3.10.1 Oceania Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Platinum based Cancer Drug Sales Volume (2016-2021)
3.11.1 South America Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.11.2 South America Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Platinum based Cancer Drug Sales Volume (2016-2021)
3.12.1 Rest of the World Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Platinum based Cancer Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Platinum based Cancer Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Platinum based Cancer Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Platinum based Cancer Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Platinum based Cancer Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Platinum based Cancer Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Platinum based Cancer Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Platinum based Cancer Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Platinum based Cancer Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Platinum based Cancer Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Platinum based Cancer Drug Sales Volume Market Share by Type (2016-2021)
14.2 Global Platinum based Cancer Drug Sales Revenue Market Share by Type (2016-2021)
14.3 Global Platinum based Cancer Drug Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Platinum based Cancer Drug Consumption Volume by Application (2016-2021)
15.2 Global Platinum based Cancer Drug Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Platinum based Cancer Drug Business
16.1 Sanofi
16.1.1 Sanofi Company Profile
16.1.2 Sanofi Platinum based Cancer Drug Product Specification
16.1.3 Sanofi Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Hengrui Medicine
16.2.1 Hengrui Medicine Company Profile
16.2.2 Hengrui Medicine Platinum based Cancer Drug Product Specification
16.2.3 Hengrui Medicine Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 ASK Pharma
16.3.1 ASK Pharma Company Profile
16.3.2 ASK Pharma Platinum based Cancer Drug Product Specification
16.3.3 ASK Pharma Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Yi Bai Pharmaceutical
16.4.1 Yi Bai Pharmaceutical Company Profile
16.4.2 Yi Bai Pharmaceutical Platinum based Cancer Drug Product Specification
16.4.3 Yi Bai Pharmaceutical Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Qilu Pharmaceutical
16.5.1 Qilu Pharmaceutical Company Profile
16.5.2 Qilu Pharmaceutical Platinum based Cancer Drug Product Specification
16.5.3 Qilu Pharmaceutical Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Teva
16.6.1 Teva Company Profile
16.6.2 Teva Platinum based Cancer Drug Product Specification
16.6.3 Teva Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Pfizer
16.7.1 Pfizer Company Profile
16.7.2 Pfizer Platinum based Cancer Drug Product Specification
16.7.3 Pfizer Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Dr Reddys Laboratories
16.8.1 Dr Reddys Laboratories Company Profile
16.8.2 Dr Reddys Laboratories Platinum based Cancer Drug Product Specification
16.8.3 Dr Reddys Laboratories Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Mylan
16.9.1 Mylan Company Profile
16.9.2 Mylan Platinum based Cancer Drug Product Specification
16.9.3 Mylan Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Sun Pharma
16.10.1 Sun Pharma Company Profile
16.10.2 Sun Pharma Platinum based Cancer Drug Product Specification
16.10.3 Sun Pharma Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Novartis
16.11.1 Novartis Company Profile
16.11.2 Novartis Platinum based Cancer Drug Product Specification
16.11.3 Novartis Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Debiopharm
16.12.1 Debiopharm Company Profile
16.12.2 Debiopharm Platinum based Cancer Drug Product Specification
16.12.3 Debiopharm Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Accord Healthcare
16.13.1 Accord Healthcare Company Profile
16.13.2 Accord Healthcare Platinum based Cancer Drug Product Specification
16.13.3 Accord Healthcare Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 SK Chemicals
16.14.1 SK Chemicals Company Profile
16.14.2 SK Chemicals Platinum based Cancer Drug Product Specification
16.14.3 SK Chemicals Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Platinum based Cancer Drug Manufacturing Cost Analysis
17.1 Platinum based Cancer Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Platinum based Cancer Drug
17.4 Platinum based Cancer Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Platinum based Cancer Drug Distributors List
18.3 Platinum based Cancer Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Platinum based Cancer Drug (2022-2027)
20.2 Global Forecasted Revenue of Platinum based Cancer Drug (2022-2027)
20.3 Global Forecasted Price of Platinum based Cancer Drug (2016-2027)
20.4 Global Forecasted Production of Platinum based Cancer Drug by Region (2022-2027)
20.4.1 North America Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.3 Europe Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.7 Africa Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.9 South America Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Platinum based Cancer Drug by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Platinum based Cancer Drug by Country
21.2 East Asia Market Forecasted Consumption of Platinum based Cancer Drug by Country
21.3 Europe Market Forecasted Consumption of Platinum based Cancer Drug by Countriy
21.4 South Asia Forecasted Consumption of Platinum based Cancer Drug by Country
21.5 Southeast Asia Forecasted Consumption of Platinum based Cancer Drug by Country
21.6 Middle East Forecasted Consumption of Platinum based Cancer Drug by Country
21.7 Africa Forecasted Consumption of Platinum based Cancer Drug by Country
21.8 Oceania Forecasted Consumption of Platinum based Cancer Drug by Country
21.9 South America Forecasted Consumption of Platinum based Cancer Drug by Country
21.10 Rest of the world Forecasted Consumption of Platinum based Cancer Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Platinum based Cancer Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Platinum based Cancer Drug Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Cisplatin
1.4.3 Oxaliplatin
1.4.4 Carboplatin
1.5 Market by Application
1.5.1 Global Platinum based Cancer Drug Market Share by Application: 2022-2027
1.5.2 Colorectal Cancer
1.5.3 Ovarian Cancer
1.5.4 Lung Cancer
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Platinum based Cancer Drug Market
1.8.1 Global Platinum based Cancer Drug Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Platinum based Cancer Drug Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Platinum based Cancer Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Platinum based Cancer Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Platinum based Cancer Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Platinum based Cancer Drug Sales Volume Market Share by Region (2016-2021)
3.2 Global Platinum based Cancer Drug Sales Revenue Market Share by Region (2016-2021)
3.3 North America Platinum based Cancer Drug Sales Volume
3.3.1 North America Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.3.2 North America Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Platinum based Cancer Drug Sales Volume
3.4.1 East Asia Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Platinum based Cancer Drug Sales Volume (2016-2021)
3.5.1 Europe Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Platinum based Cancer Drug Sales Volume (2016-2021)
3.6.1 South Asia Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Platinum based Cancer Drug Sales Volume (2016-2021)
3.7.1 Southeast Asia Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Platinum based Cancer Drug Sales Volume (2016-2021)
3.8.1 Middle East Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Platinum based Cancer Drug Sales Volume (2016-2021)
3.9.1 Africa Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Platinum based Cancer Drug Sales Volume (2016-2021)
3.10.1 Oceania Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Platinum based Cancer Drug Sales Volume (2016-2021)
3.11.1 South America Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.11.2 South America Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Platinum based Cancer Drug Sales Volume (2016-2021)
3.12.1 Rest of the World Platinum based Cancer Drug Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Platinum based Cancer Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Platinum based Cancer Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Platinum based Cancer Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Platinum based Cancer Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Platinum based Cancer Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Platinum based Cancer Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Platinum based Cancer Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Platinum based Cancer Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Platinum based Cancer Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Platinum based Cancer Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Platinum based Cancer Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Platinum based Cancer Drug Sales Volume Market Share by Type (2016-2021)
14.2 Global Platinum based Cancer Drug Sales Revenue Market Share by Type (2016-2021)
14.3 Global Platinum based Cancer Drug Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Platinum based Cancer Drug Consumption Volume by Application (2016-2021)
15.2 Global Platinum based Cancer Drug Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Platinum based Cancer Drug Business
16.1 Sanofi
16.1.1 Sanofi Company Profile
16.1.2 Sanofi Platinum based Cancer Drug Product Specification
16.1.3 Sanofi Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Hengrui Medicine
16.2.1 Hengrui Medicine Company Profile
16.2.2 Hengrui Medicine Platinum based Cancer Drug Product Specification
16.2.3 Hengrui Medicine Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 ASK Pharma
16.3.1 ASK Pharma Company Profile
16.3.2 ASK Pharma Platinum based Cancer Drug Product Specification
16.3.3 ASK Pharma Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Yi Bai Pharmaceutical
16.4.1 Yi Bai Pharmaceutical Company Profile
16.4.2 Yi Bai Pharmaceutical Platinum based Cancer Drug Product Specification
16.4.3 Yi Bai Pharmaceutical Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Qilu Pharmaceutical
16.5.1 Qilu Pharmaceutical Company Profile
16.5.2 Qilu Pharmaceutical Platinum based Cancer Drug Product Specification
16.5.3 Qilu Pharmaceutical Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Teva
16.6.1 Teva Company Profile
16.6.2 Teva Platinum based Cancer Drug Product Specification
16.6.3 Teva Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Pfizer
16.7.1 Pfizer Company Profile
16.7.2 Pfizer Platinum based Cancer Drug Product Specification
16.7.3 Pfizer Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Dr Reddys Laboratories
16.8.1 Dr Reddys Laboratories Company Profile
16.8.2 Dr Reddys Laboratories Platinum based Cancer Drug Product Specification
16.8.3 Dr Reddys Laboratories Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Mylan
16.9.1 Mylan Company Profile
16.9.2 Mylan Platinum based Cancer Drug Product Specification
16.9.3 Mylan Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Sun Pharma
16.10.1 Sun Pharma Company Profile
16.10.2 Sun Pharma Platinum based Cancer Drug Product Specification
16.10.3 Sun Pharma Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Novartis
16.11.1 Novartis Company Profile
16.11.2 Novartis Platinum based Cancer Drug Product Specification
16.11.3 Novartis Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Debiopharm
16.12.1 Debiopharm Company Profile
16.12.2 Debiopharm Platinum based Cancer Drug Product Specification
16.12.3 Debiopharm Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Accord Healthcare
16.13.1 Accord Healthcare Company Profile
16.13.2 Accord Healthcare Platinum based Cancer Drug Product Specification
16.13.3 Accord Healthcare Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 SK Chemicals
16.14.1 SK Chemicals Company Profile
16.14.2 SK Chemicals Platinum based Cancer Drug Product Specification
16.14.3 SK Chemicals Platinum based Cancer Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Platinum based Cancer Drug Manufacturing Cost Analysis
17.1 Platinum based Cancer Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Platinum based Cancer Drug
17.4 Platinum based Cancer Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Platinum based Cancer Drug Distributors List
18.3 Platinum based Cancer Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Platinum based Cancer Drug (2022-2027)
20.2 Global Forecasted Revenue of Platinum based Cancer Drug (2022-2027)
20.3 Global Forecasted Price of Platinum based Cancer Drug (2016-2027)
20.4 Global Forecasted Production of Platinum based Cancer Drug by Region (2022-2027)
20.4.1 North America Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.3 Europe Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.7 Africa Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.9 South America Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Platinum based Cancer Drug Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Platinum based Cancer Drug by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Platinum based Cancer Drug by Country
21.2 East Asia Market Forecasted Consumption of Platinum based Cancer Drug by Country
21.3 Europe Market Forecasted Consumption of Platinum based Cancer Drug by Countriy
21.4 South Asia Forecasted Consumption of Platinum based Cancer Drug by Country
21.5 Southeast Asia Forecasted Consumption of Platinum based Cancer Drug by Country
21.6 Middle East Forecasted Consumption of Platinum based Cancer Drug by Country
21.7 Africa Forecasted Consumption of Platinum based Cancer Drug by Country
21.8 Oceania Forecasted Consumption of Platinum based Cancer Drug by Country
21.9 South America Forecasted Consumption of Platinum based Cancer Drug by Country
21.10 Rest of the world Forecasted Consumption of Platinum based Cancer Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Published On:2024/07/06
Base Year:
Historical Data:
No of Pages:165
Price
Global Platinum based Cancer Drug Market Research Report 2024 - Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2031
A2Z Market Research is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
Subscribe Us
Sign up today for tips and latest news
and exclusive special offers.
